<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00101452</url>
  </required_header>
  <id_info>
    <org_study_id>R01AT001638-01A1</org_study_id>
    <secondary_id>R01AT001638-01A1</secondary_id>
    <nct_id>NCT00101452</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of S-adenosyl-l-methionine (SAMe) for the Treatment of Major Depression</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Study of the Alternative Therapy S-Adenosyl-L-Methionine (SAMe) vs Escitalopram in Major Depressive Disorder (MDD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maurizio Fava, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and effectiveness of
      s-adenosyl-l-methionine (SAMe) in treating major depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SAMe is a substance that is naturally produced by the body and is also sold as an
      over-the-counter drug. Although SAMe has not yet been approved for treating depression,
      evidence suggests that it has antidepressant properties. This study will determine whether
      SAMe is safe and effective in treating major depression.

      This study will last 24 weeks. Participants will be randomly assigned to receive either the
      antidepressant escitalopram, SAMe, or placebo for 12 weeks. Participants who respond to
      treatment at the end of 12 weeks will stay on their regimen for an additional 12 weeks.
      Participants who do not respond to treatment will enter an open treatment phase where they
      will receive SAMe and escitalopram for 12 more weeks. Depression scales and self-report
      questionnaires will be used to assess participants. All participants will receive 3 months of
      follow-up care, including free medication and clinic visits as necessary.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Rating Scale for Depression (HAM-D)</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>The change in total HAM-D score between baseline and endpoint was the primary outcomes measure. This measure is a clinician rated inventory of depressive symptoms. All items are scored on a scale of zero to four and the sum of the scores provides the total score for the measure. Scores can range from 0- 68. On this scale, higher scores indicate poorer outcomes.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">199</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>S-adenosyl-l-methionine (SAMe)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A natural substance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Escitalopram</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A selective serotonin reuptake inhibitor (SSRI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3. placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sugar pill- contains no active ingredients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-adenosyl-l-methionine</intervention_name>
    <description>1600 mg per day with possibility of increasing to 3200 mg per day at 6 weeks</description>
    <arm_group_label>S-adenosyl-l-methionine (SAMe)</arm_group_label>
    <other_name>SAMe</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>10 mg per day, with possibility of increasing to 20 mg/day at 6 weeks</description>
    <arm_group_label>2. Escitalopram</arm_group_label>
    <other_name>Lexapro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo capsules look like escitalopram capsules and SAMe capsules</description>
    <arm_group_label>3. placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of major depression

          -  Score of 25 or higher on the Inventory of Depressive Symptomatology (IDS-C) scale

          -  Score of higher than 2 on the Clinical Global Impression Improvement (CGI) scale

          -  Willing to use acceptable methods of contraception

        Exclusion Criteria:

          -  Suicidal or homicidal

          -  Unstable illness, including cardiovascular, hepatic, renal, respiratory, endocrine,
             neurological, or hematological disease.

          -  Any of the following mental conditions: organic mental disorders; schizophrenia;
             delusional disorder; psychotic disorders; bipolar disorder; recent bereavement; severe
             borderline or antisocial personality disorder; panic disorder; or obsessive compulsive
             disorder

          -  Substance abuse, including alcohol abuse, within 6 months prior to study entry

          -  Uncontrolled seizure disorder, or a seizure disorder controlled with psychotropic
             anticonvulsants

          -  Psychotic features

          -  Current use of other psychotropic drugs

          -  Hypothyroidism

          -  Have taken 6 weeks or more of either escitalopram or SAMe during the current
             depressive episode

          -  Previous intolerance of SAMe or escitalopram

          -  Investigational psychotropic drugs within 1 year prior to study entry

          -  Have received two or more antidepressant therapies of adequate doses and duration and
             failed to respond

          -  Have received depression-focused psychotherapy

          -  Bleeding tissue disorder, low platelet counts, a history of GI bleeding, or use of
             medications that alter bleeding risk

          -  Long-term aspirin use

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurizio Fava, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Butler Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Mischoulon D, Price LH, Carpenter LL, Tyrka AR, Papakostas GI, Baer L, Dording CM, Clain AJ, Durham K, Walker R, Ludington E, Fava M. A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder. J Clin Psychiatry. 2014 Apr;75(4):370-6. doi: 10.4088/JCP.13m08591.</citation>
    <PMID>24500245</PMID>
  </results_reference>
  <results_reference>
    <citation>Sarris J, Price LH, Carpenter LL, Tyrka AR, Ng CH, Papakostas GI, Jaeger A, Fava M, Mischoulon D. Is S-Adenosyl Methionine (SAMe) for Depression Only Effective in Males? A Re-Analysis of Data from a Randomized Clinical Trial. Pharmacopsychiatry. 2015 Jul;48(4-5):141-4. doi: 10.1055/s-0035-1549928. Epub 2015 May 26.</citation>
    <PMID>26011569</PMID>
  </results_reference>
  <results_reference>
    <citation>Mischoulon D, Price LH, Carpenter LL, Tyrka AR, Papakostas GI, Fava M. Dr. Mischoulon and colleagues reply. J Clin Psychiatry. 2014 Nov;75(11):e1328-9. doi: 10.4088/JCP.14lr09266a.</citation>
    <PMID>25470103</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2005</study_first_submitted>
  <study_first_submitted_qc>January 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2005</study_first_posted>
  <results_first_submitted>June 13, 2012</results_first_submitted>
  <results_first_submitted_qc>November 29, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 31, 2012</results_first_posted>
  <last_update_submitted>March 6, 2017</last_update_submitted>
  <last_update_submitted_qc>March 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Maurizio Fava, MD</investigator_full_name>
    <investigator_title>Director- Depression Clinical and Research Program</investigator_title>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Antidepressive Agents</keyword>
  <keyword>Complementary Therapies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited through general advertising at both the Depression Clinical and Research Program of MGH in Boston, MA and Butler Hospital in Providence, RI. Recruitment also took place at Family Doctors, LLC, in Swampscott, MA. We began recruiting participants in April 2005 and closed the study in December of 2009.</recruitment_details>
      <pre_assignment_details>Only five participants completed the allowed wash-out period prior to randomization. Participants screened at Day 0-7 and were asked to return for a baseline visit at Day 0. Subjects not randomized were excluded for being ineligible at the baseline or for being lost to follow-up between screen and baseline.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1. SAMe</title>
          <description>Patients start with 1600mg/day for the first. If they do not feel better after 6 weeks, they may increase to 3200mg/day if their lab tests are normal.</description>
        </group>
        <group group_id="P2">
          <title>2. Escitalopram</title>
          <description>Patients start with 10mg/day for the first 6 weeks. If they do not feel better after 6 weeks, they can increase to 20mg/day.</description>
        </group>
        <group group_id="P3">
          <title>3. Placebo</title>
          <description>Placebo is a non-active treatment, sometimes called a sugar pill.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="69"/>
                <participants group_id="P3" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="43"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Baseline Fail</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1. SAMe</title>
          <description>a naturally occurring substance</description>
        </group>
        <group group_id="B2">
          <title>2. Escitalopram</title>
          <description>A selective serotonin reuptake inhibitor (SSRI)</description>
        </group>
        <group group_id="B3">
          <title>3. Placebo</title>
          <description>Sugar Pill- contains no active ingrediants</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="59"/>
            <count group_id="B2" value="55"/>
            <count group_id="B3" value="52"/>
            <count group_id="B4" value="166"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>The number of patients originally enrolled does not match the number of patients who completed baseline assessments because some patients dropped out of the study after the screening visit and therefore never completed the baseline visit.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="157"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>The number of patients originally enrolled does not match the number of patients who completed baseline assessments because some patients dropped out of the study after the screening visit and therefore never completed the baseline visit.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.25" spread="13.98"/>
                    <measurement group_id="B2" value="44.67" spread="14.29"/>
                    <measurement group_id="B3" value="44.34" spread="15.19"/>
                    <measurement group_id="B4" value="44.75" spread="14.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>The number of patients originally enrolled does not match the number of patients who completed baseline assessments because some patients dropped out of the study after the screening visit and therefore never completed the baseline visit.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>The number of patients originally enrolled does not match the number of patients who completed baseline assessments because some patients dropped out of the study after the screening visit and therefore never completed the baseline visit.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hamilton Rating Scale for Depression (HAM-D)</title>
        <description>The change in total HAM-D score between baseline and endpoint was the primary outcomes measure. This measure is a clinician rated inventory of depressive symptoms. All items are scored on a scale of zero to four and the sum of the scores provides the total score for the measure. Scores can range from 0- 68. On this scale, higher scores indicate poorer outcomes.</description>
        <time_frame>baseline and 24 weeks</time_frame>
        <population>Based on having at least one post-baseline visit.</population>
        <group_list>
          <group group_id="O1">
            <title>1. SAMe</title>
            <description>a naturally occurring substance</description>
          </group>
          <group group_id="O2">
            <title>2. Escitalopram</title>
            <description>A selective serotonin reuptake inhibitor (SSRI)</description>
          </group>
          <group group_id="O3">
            <title>3. Placebo</title>
            <description>Sugar Pill- contains no active ingrediants</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Rating Scale for Depression (HAM-D)</title>
          <description>The change in total HAM-D score between baseline and endpoint was the primary outcomes measure. This measure is a clinician rated inventory of depressive symptoms. All items are scored on a scale of zero to four and the sum of the scores provides the total score for the measure. Scores can range from 0- 68. On this scale, higher scores indicate poorer outcomes.</description>
          <population>Based on having at least one post-baseline visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.7" spread="7.3"/>
                    <measurement group_id="O2" value="-7.5" spread="7.4"/>
                    <measurement group_id="O3" value="-5.7" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events for SAMe, escitalopram, and placebo, were reported during the 12 week double blind course of the study and during the 12-week open cross over phase that followed the acute treatment phase.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1. SAMe (Weeks 1-12)</title>
          <description>A naturally occurring substance (S-adenosyl methionine)</description>
        </group>
        <group group_id="E2">
          <title>2. Escitalopram (Weeks 1-12)</title>
          <description>A selective serotonin reuptake inhibitor (SSRI)</description>
        </group>
        <group group_id="E3">
          <title>3. Placebo (Weeks 1-12)</title>
          <description>Sugar Pill- contains no active ingredients</description>
        </group>
        <group group_id="E4">
          <title>4. SAMe (Weeks 12-24, Continuation)</title>
          <description>A naturally occurring substance (S-adenosyl methionine)</description>
        </group>
        <group group_id="E5">
          <title>5. Escitalopram (Weeks 12-24, Continuation)</title>
          <description>A selective serotonin reuptake inhibitor (SSRI)</description>
        </group>
        <group group_id="E6">
          <title>6. Placebo (Weeks 12-24, Continuation)</title>
          <description>Sugar Pill- contains no active ingredients</description>
        </group>
        <group group_id="E7">
          <title>7. SAMe Plus Escitalopram (Weeks 12-24, Cross-over)</title>
          <description>A naturally occurring substance (S-adenosyl methionine) plus a selective serotonin reuptake inhibitor (SSRI)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="29" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="59"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="55"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="52"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="17"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="11"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E7" events="16" subjects_affected="16" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Somatic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="17"/>
                <counts group_id="E5" events="9" subjects_affected="9" subjects_at_risk="11"/>
                <counts group_id="E6" events="10" subjects_affected="10" subjects_at_risk="15"/>
                <counts group_id="E7" events="15" subjects_affected="15" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Sexual dysfunction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E7" events="7" subjects_affected="7" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Maurizio Fava</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-724-2513</phone>
      <email>mfava@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

